Header Logo

Connection

Bruce Woda to Biomarkers, Tumor

This is a "connection" page, showing publications Bruce Woda has written about Biomarkers, Tumor.
Connection Strength

1.366
  1. Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget. 2016 Sep 13; 7(37):59976-59986.
    View in: PubMed
    Score: 0.104
  2. Xiao R, Cerny J, Devitt K, Dresser K, Nath R, Ramanathan M, Rodig SJ, Chen BJ, Woda BA, Yu H. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS). Am J Surg Pathol. 2014 Jun; 38(6):776-83.
    View in: PubMed
    Score: 0.089
  3. Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 2014 May; 21(3):191-200.
    View in: PubMed
    Score: 0.088
  4. Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 2011 Nov; 35(11):1638-45.
    View in: PubMed
    Score: 0.074
  5. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY. Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol. 2009 Jul; 22(7):977-84.
    View in: PubMed
    Score: 0.062
  6. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009 Apr; 33(4):521-5.
    View in: PubMed
    Score: 0.062
  7. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1648-52.
    View in: PubMed
    Score: 0.059
  8. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008 Jun 15; 112(12):2676-82.
    View in: PubMed
    Score: 0.059
  9. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007 Dec; 20(12):1263-8.
    View in: PubMed
    Score: 0.056
  10. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007 Feb; 20(2):242-7.
    View in: PubMed
    Score: 0.053
  11. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006 Jul; 7(7):556-64.
    View in: PubMed
    Score: 0.051
  12. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005 Feb; 29(2):188-95.
    View in: PubMed
    Score: 0.046
  13. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005 Feb; 123(2):231-6.
    View in: PubMed
    Score: 0.046
  14. Jiang Z, Woda BA. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol. 2004 Nov; 11(6):316-21.
    View in: PubMed
    Score: 0.046
  15. Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova MS, Young RH, Weiss LM, Blute RD, Brendler CB, Krausz T, Xu JC, Rock KL, Amin MB, Yang XJ. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004 Sep; 45(3):218-25.
    View in: PubMed
    Score: 0.045
  16. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol. 2004 Aug; 122(2):275-89.
    View in: PubMed
    Score: 0.045
  17. Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, Xu J, Reed SG, Rock KL, Chu PG. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev. 2003; 27(6):422-6.
    View in: PubMed
    Score: 0.040
  18. Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, Jiang Z. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002 Jul; 26(7):921-5.
    View in: PubMed
    Score: 0.039
  19. Jiang Z, Woda BA, Yang XJ. Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer. JAMA. 2002 Jun 19; 287(23):3080-1; author reply 3081.
    View in: PubMed
    Score: 0.039
  20. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001 Nov; 25(11):1397-404.
    View in: PubMed
    Score: 0.037
  21. Moore BE, Banner BF, Gokden M, Woda B, Liu Y, Ayala A, Jiang Z. p53: a good diagnostic marker for intratubular germ cell neoplasia, unclassified. Appl Immunohistochem Mol Morphol. 2001 Sep; 9(3):203-6.
    View in: PubMed
    Score: 0.037
  22. Magotra M, Sakhdari A, Lee PJ, Tomaszewicz K, Dresser K, Hutchinson LM, Woda BA, Chen BJ. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways. Histopathology. 2016 Dec; 69(6):1055-1065.
    View in: PubMed
    Score: 0.026
  23. Gao Y, Yang M, Jiang Z, Woda BA, Mercurio AM, Qin J, Huang X, Zhang F. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma. Hum Pathol. 2014 Jun; 45(6):1184-91.
    View in: PubMed
    Score: 0.022
  24. Hao S, Smith TW, Chu PG, Liu Q, Ok CY, Woda BA, Lu D, Lin P, Wang SA, Dresser K, Rock KL, Jiang Z. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med. 2011 Aug; 135(8):1032-6.
    View in: PubMed
    Score: 0.018
  25. Zhang L, Liu Y, Hao S, Woda BA, Lu D. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol. 2011 Jun; 35(6):868-72.
    View in: PubMed
    Score: 0.018
  26. Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011 Jun; 35(6):878-82.
    View in: PubMed
    Score: 0.018
  27. Lisovsky M, Dresser K, Woda B, Mino-Kenudson M. Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol. 2010 Jun; 41(6):902-9.
    View in: PubMed
    Score: 0.017
  28. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008 Mar 15; 14(6):1701-6.
    View in: PubMed
    Score: 0.014
  29. Rosenwald IB, Koifman L, Savas L, Chen JJ, Woda BA, Kadin ME. Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma. Hum Pathol. 2008 Jun; 39(6):910-6.
    View in: PubMed
    Score: 0.014
  30. Wu CL, Yang XJ, Tretiakova M, Patton KT, Halpern EF, Woda BA, Young RH, Jiang Z. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2004 Aug; 35(8):1008-13.
    View in: PubMed
    Score: 0.011
  31. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004 Jan; 121(1):99-107.
    View in: PubMed
    Score: 0.011
  32. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
    View in: PubMed
    Score: 0.010
  33. Jiang Z, Wu CL, Woda BA, Dresser K, Xu J, Fanger GR, Yang XJ. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002 Sep; 26(9):1169-74.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.